Stock Hub

ACET
Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. Use the sections below to move between chart, technical analysis, fundamentals, and news.

Latest Close

$2.14

1y Change

-$7.49 (-77.78%)

Market Cap

$20,033,816.00

Sector

Healthcare

Industry

Biotechnology

Recommendation

none

52W Range

$2.12 to $11.15

Target Mean Price

$29.00

Beta

1.74

Trailing P/E

Not available

Forward P/E

-0.44

Price / Book

0.22

Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Website: https://www.adicetbio.com